Search Results - "Fellman, C."

Refine Results
  1. 1

    Digital CBT-I versus stepped-care CBT-I to prevent depression one year later by Cheng, P, Kalmbach, D, Sagong, C, Fellman-Couture, C, Drake, C

    Published in European psychiatry (01-03-2023)
    “…IntroductionInsomnia is a robust risk factor for depression. Treating insomnia with digital CBT-I (dCBT-I) has been shown to prevent future episodes of…”
    Get full text
    Journal Article
  2. 2

    Oral Cyclosporine Treatment in Dogs: A Review of the Literature by Archer, T.M, Boothe, D.M, Langston, V.C, Fellman, C.L, Lunsford, K.V, Mackin, A.J

    Published in Journal of veterinary internal medicine (01-01-2014)
    “…Cyclosporine is an immunomodulatory drug used to treat an increasing spectrum of diseases in dogs. Cyclosporine is a calcineurin inhibitor, ultimately exerting…”
    Get full text
    Journal Article
  3. 3

    In vivo effects of aspirin and cyclosporine on regulatory T cells and T-cell cytokine production in healthy dogs by Archer, T.M., Stokes, J.V., Kummari, E., Fellman, C., Thomason, J., Haraschak, J., Wills, R., Pinchuk, L., Mackin, A.

    Published in Veterinary immunology and immunopathology (01-03-2018)
    “…•Cyclosporine significantly decreased IL-2 and IFN-γ expression.•High-dose aspirin, but not low-dose aspirin, significantly decreased IL-2 expression.•No drug…”
    Get full text
    Journal Article
  4. 4

    Immune-mediated hematological disease in dogs is associated with alterations of the fecal microbiota: a pilot study by Liu, P.-Y., Xia, D., McGonigle, K., Carroll, A. B., Chiango, J., Scavello, H., Martins, R., Mehta, S., Krespan, E., Lunde, E., LeVine, D., Fellman, C. L., Goggs, R., Beiting, D. P., Garden, O. A.

    Published in Animal microbiome (29-09-2023)
    “…Abstract Background The dog is the most popular companion animal and is a valuable large animal model for several human diseases. Canine immune-mediated…”
    Get full text
    Journal Article
  5. 5

    Effects of oral cyclosporine on canine T‐cell expression of IL‐2 and IFN‐gamma across a 12‐h dosing interval by Fellman, C. L., Archer, T. M., Stokes, J. V., Wills, R. W., Lunsford, K. V., Mackin, A. J.

    “…The duration of immunosuppressive effects following oral cyclosporine in dogs is unknown. This study used flow cytometry and quantitative reverse…”
    Get full text
    Journal Article
  6. 6

    Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs by Fellman, C.L., Stokes, J.V., Archer, T.M., Pinchuk, L.M., Lunsford, K.V., Mackin, A.J.

    Published in Veterinary immunology and immunopathology (15-04-2011)
    “…Cyclosporine is a powerful immunosuppressive drug that is being used with increasing frequency to treat a wide range of immune-mediated diseases in the dog. To…”
    Get full text
    Journal Article
  7. 7

    Pharmacodynamic Monitoring of Canine T-Cell Cytokine Responses to Oral Cyclosporine by Archer, T.M., Fellman, C.L., Stokes, J.V., Pinchuk, L.M., Lunsford, K.V., Pruett, S.B., Langston, V.C., Mackin, A.J.

    Published in Journal of veterinary internal medicine (01-11-2011)
    “…Background Pharmacodynamic assays measure the immunosuppressive effects of cyclosporine on T‐cells and offer an alternative assessment of efficacy in…”
    Get full text
    Journal Article
  8. 8

    Analytical validation of a quantitative reverse transcriptase polymerase chain reaction assay for evaluation of T-cell targeted immunosuppressive therapy in the dog by Riggs, C., Archer, T., Fellman, C., Figueiredo, A.S., Follows, J., Stokes, J., Wills, R., Mackin, A., Bulla, C.

    Published in Veterinary immunology and immunopathology (15-12-2013)
    “…Cyclosporine is an immunosuppressive agent that inhibits T-cell function by decreasing production of cytokines such as interleukin-2 (IL-2) and interferon-γ…”
    Get full text
    Journal Article
  9. 9

    Pharmacokinetic evaluation of oral dantrolene in the dog by Haraschak, J. L, Langston, V. C, Wang, R, Riggs, C, Fellman, C, Ross, M. K, Bulla, C, Lunsford, K, Mackin, A, Archer, T

    “…The pharmacokinetics of dantrolene and its active metabolite, 5‐hydroxydantrolene, after a single oral dose of either 5 or 10 mg/kg of dantrolene was…”
    Get full text
    Journal Article
  10. 10

    0397 Impact of Behavioral Insomnia Treatments on Quality of Life in Post-Menopausal Women by Tallent, G, Cheng, P, Fellman-Couture, C, Tonnu, C, Moss, K, Arnedt, T, Drake, C

    Published in Sleep (New York, N.Y.) (27-04-2018)
    “…Abstract Introduction Insomnia in post-menopausal women is commonly associated with reduced quality of life. Preliminary data suggest that both Cognitive…”
    Get full text
    Journal Article
  11. 11

    0706 Impact of Behavioral Insomnia Treatment on Post-Menopausal Female Sexual Functioning by Tonnu, C V, Cheng, P, Kalmbach, D, Fellman-Couture, C, Tallent, G, Arnedt, J, Singh, M, Drake, C

    Published in Sleep (New York, N.Y.) (27-04-2018)
    “…Abstract Introduction Sexual difficulties are commonly reported in post-menopausal women, and can be worsened by insomnia. Although highly prevalent, insomnia…”
    Get full text
    Journal Article
  12. 12

    0394 Efficacy of Cognitive Behavioral Therapy for Insomnia on Post-Menopausal Quality of Life by Arnedt, J T, Cheng, P, Fellman-Couture, C, Tallent, G, Kalmbach, D, Singh, M, Roth, T, Drake, C L

    Published in Sleep (New York, N.Y.) (27-04-2018)
    “…Abstract Introduction Insomnia occurs in more than 50% of post-menopausal women, is among the most distressing and debilitating symptoms, and adversely affects…”
    Get full text
    Journal Article
  13. 13

    1086 CBT-I FOR MENOPAUSE RELATED INSOMNIA ALSO REDUCES DEPRESSION SEVERITY by Cheng, P, Fellman-Couture, C, Ahmedani, B, Tallent, G, Arnedt, J, Roehrs, T, Roth, T, Drake, C

    Published in Sleep (New York, N.Y.) (28-04-2017)
    “…Abstract Introduction: Menopause has been associated with elevated risk of mood disturbances. This relationship has been attributed to a number of factors…”
    Get full text
    Journal Article
  14. 14

    0375 Long-term Efficacy of the Sleep to Prevent Evolving Affective Disorders (SPREAD) Trial as an Internet-based Treatment for Insomnia by Cuamatzi-Castelan, A S, Cheng, P, Fellman-Couture, C, Tallent, G, Tran, K M, Espie, C A, Joseph, C, Roehrs, T, Drake, C L

    Published in Sleep (New York, N.Y.) (27-04-2018)
    “…Abstract Introduction A growing body of evidence supports the acute benefits of internet-based interventions for insomnia; however, the durability of the acute…”
    Get full text
    Journal Article
  15. 15
  16. 16

    0359 EFFICACY OF BEHAVIORAL INSOMNIA TREATMENT ON POST-MENOPAUSAL QUALITY OF LIFE by Hyde-Nolan, ME, Arnedt, JT, Cheng, P, Fellman-Couture, C, Tallent, G, Kalmbach, D, Singh, M, Roth, T, Drake, CL

    Published in Sleep (New York, N.Y.) (28-04-2017)
    “…Abstract Introduction: Insomnia and reduced quality of life are very common among post-menopausal women. We examined the efficacy of Cognitive Behavioral…”
    Get full text
    Journal Article
  17. 17

    Sexual function and distress in postmenopausal women with chronic insomnia: exploring the role of stress dysregulation by Kalmbach, David A, Kingsberg, Sheryl A, Roth, Thomas, Cheng, Philip, Fellman-Couture, Cynthia, Drake, Christopher L

    Published in Nature and science of sleep (01-08-2019)
    “…Menopause triggers changes in sexual function and many women develop sexual problems. Insomnia is common in postmenopausal women, and disturbed sleep has been…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20